Healthcare / BiotechnologyNasdaqCM
$1.42
-0.16 (-10.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-37.8M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$150M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-85.4%
↓Gross Margin
N/A
•Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+64.2%
FCF CAGR
—
FCF margin
-338.3%
FCF / Net income
1.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.9M · net income $-42.2M · FCF $-53.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.9M | $15.9M | $18.9M | $6.5M | $3.6M |
| Net Income | $-42.2M | $-42.2M | $-27.8M | $-28.1M | $-64.4M |
| EBITDA | $-38.5M | $-38.5M | $-24.1M | $-24.1M | $-56.5M |
| EPS | — | — | -0.32 | -0.35 | -0.90 |
| Operating Margin | -273.1% | -273.1% | -161.2% | -534.1% | -1813.0% |
| Net Margin | -265.2% | -265.2% | -146.9% | -431.7% | -1792.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.19 | 0.48 | 0.33 |
| Current Ratio | 2.48 | 2.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-53.8M | $-53.8M | $-37.8M | $20.2M | $-69.2M |
| Returns | |||||
| ROE | -85.4% | -85.4% | -31.3% | -67.9% | -96.1% |
| Valuation | |||||
| P/B | 3.03 | 3.03 | 2.68 | 3.96 | 3.81 |
| Growth & Yield | |||||
| Revenue Growth | -15.9% | -15.9% | 190.2% | 81.2% | — |
| EPS Growth | — | — | 8.6% | 61.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.32 → n/d
Residual
-14.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.